AtriCure (ATRC) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to AtriCure (ATRC) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

AtriCure Reports First Quarter 2021 Financial Results

April 27, 2021 4:01 PM EDT

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results.

Our growth in the first quarter is a testament of our teams strong execution and unwavering dedication despite continued COVID headwinds, said Michael Carrel, President and Chief Executive Officer of AtriCure. As we navigate toward a return to normalcy, I am confident that we are extremely well positioned for the future with our pathway of growth catalysts and the realization of these opportunities underway, beginning... More